openPR Logo
Press release

GSK plc (NYSE: GSK) Investor Alert: Deadline in Lawsuit on April 7, 2025

A Deadline is coming up on April 7, 2025in the lawsuit for certain investors in GSK plc (NYSE: GSK) and GSK plc (NYSE: GSK) stockh

A Deadline is coming up on April 7, 2025in the lawsuit for certain investors in GSK plc (NYSE: GSK) and GSK plc (NYSE: GSK) stockh

A deadline is coming up on April 7, 2025 in the lawsuit filed for certain investors of GSK plc (NYSE: GSK) over alleged securities laws violations by GSK plc.

Investors who purchased shares of GSK plc (NYSE: GSK) have certain options and there are strict and short deadlines running. Deadline: April 7, 2025. GSK plc (NYSE: GSK) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges on behalf of purchasers of GSK plc (NYSE: GSK) common shares between February 5, 2020, and August 14, 2022, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 5, 2020, and August 14, 2022, the Defendants represented to investors that GSK removed Zantac from the market "[b]ased on information available at the time and correspondence with regulators," that GSK was "continuing with investigations into the potential source of NDMA", that the Defendants also assured investors that "GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients," findings that were "consistent with other ranitidine data published prior to 2019", and that the Defendants claimed that they could not "quantify or reliably estimate the liability" GSK could face from Zantac-related legal proceedings.

Those who purchased shares of GSK plc (NYSE: GSK) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release GSK plc (NYSE: GSK) Investor Alert: Deadline in Lawsuit on April 7, 2025 here

News-ID: 3933980 • Views:

More Releases from Shareholders Foundation, Inc.

Long-Term Investors in shares of ModivCare Inc. (NASDAQ: MODV) should contact the Shareholders Foundation in connection with Investigation over potential Wrongdoing
Long-Term Investors in shares of ModivCare Inc. (NASDAQ: MODV) should contact th …
An investigation was announced for long-term investors in shares of ModivCare Inc. (NASDAQ: MODV) concerning potential breaches of fiduciary duties by certain directors of ModivCare Inc. Investors who are current long term investors in ModivCare Inc. (NASDAQ: MODV) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: MODV stocks
Fluence Energy, Inc. (NASDAQ: FLNC) Investor Notice: Deadline in Lawsuit on May 12, 2025 coming up
Fluence Energy, Inc. (NASDAQ: FLNC) Investor Notice: Deadline in Lawsuit on May …
The Shareholders Foundation announced that a deadline is coming up on May 12, 2025 in the lawsuit filed for certain investors of Fluence Energy, Inc. (NASDAQ: FLNC) over alleged securities laws violations by Fluence Energy, Inc. Investors who purchased shares of Fluence Energy, Inc. (NASDAQ: FLNC) have certain options and there are strict and short deadlines running. Deadline: May 12, 2025. NASDAQ: FLNC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Investigation announced for Long-Term Investors in Nextracker Inc. (NASDAQ: NXT) concerning potential Wrongdoing
Investigation announced for Long-Term Investors in Nextracker Inc. (NASDAQ: NXT) …
An investigation was announced over potential breaches of fiduciary duties by certain directors and officers of Nextracker Inc. Investors who are current long term investors in Nextracker Inc. (NASDAQ: NXT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: NXT stocks follows a lawsuit filed against Nextracker Inc. over
AppLovin Corporation (NASDAQ: APP) Investor Alert: Deadline in Lawsuit on May 5, 2025
AppLovin Corporation (NASDAQ: APP) Investor Alert: Deadline in Lawsuit on May 5, …
A deadline is coming up on May 5, 2025 in the lawsuit filed for certain investors of AppLovin Corporation (NASDAQ: APP) over alleged securities laws violations by AppLovin Corporation. Investors who purchased shares of AppLovin Corporation (NASDAQ: APP) have certain options and there are strict and short deadlines running. Deadline: May 5, 2025. AppLovin Corporation (NASDAQ: APP) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According

All 5 Releases


More Releases for GSK

Investigation announced for Investors in shares of GSK plc (NYSE: GSK) over poss …
An investigation was announced for investors of GSK plc (NYSE: GSK) shares over potential securities laws violations by GSK plc. Investors who purchased shares of GSK plc (NYSE: GSK), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by GSK plc regarding its business, its prospects and its operations were materially
Vaccines Industry Market Growth Prospects And Outlook 2022-2027| GSK, Sanofi, Me …
The Vaccines market outlook looks extremely promising is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain, future roadmaps and its distributor analysis. This Market study provides comprehensive data that enhances the understanding, scope, and application of this report. Top Companies in the Global
2019-2024 | Vaccines Market Top Business Players: Vaccines Market GSK, Sanofi, …
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily
Vaccines Market 2018 Competitive Situation, Market Concentration Rate and Growth …
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily
Melphalan Market 2017-2022 GSK, NATCO, Aspen, …
Global Melphalan Market Size, Status and Forecast 2022 provides Market information about Manufacturers, Countries, Type and Application.This Industry report also states Company Profile, sales, Melphalan Market revenue and price, market share, market growth and gross margin by regions. Top Manufacturers/Key Players: GSK NATCO Aspen … Download Free Sample Copy Of this Report @ https://goo.gl/AXnC1c This report provides detailed analysis of worldwide markets for Melphalan and provides extensive market forecasts 2017-2022 by region/country and subsectors. It covers
Alkeran Market 2017-2022 GSK, NATCO, Aspen, …
Global Alkeran Market Size, Status and Forecast 2022 provides Market information about Manufacturers, Countries, Type and Application.This Industry report also states Company Profile, sales, Alkeran Market revenue and price, market share, market growth and gross margin by regions. Top Manufacturers/Key Players: GSK NATCO Aspen … Download Free Sample Copy Of this Report @ https://goo.gl/aatFA1 This report provides detailed analysis of worldwide markets for Alkeran and provides extensive market forecasts 2017-2022 by region/country and subsectors. It covers